Skip to main content

Table 3 1-Year Outcomes in HF Population Stratified by LVEF

From: Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China

 

HFrEF (n = 211)

HFmrEF (n = 201)

HFpEF (n = 343)

p value

Univariate analysis

 

HFmrEF vs HFrEF

HFmrEF vs HFpEF

HR/OR (95% CI)

p value

HR/OR (95% CI)

p value

All-cause Mortality

26 (12.3%)

11 (5.5%)

16 (4.7%)

0.002

0.461 (0.227–0.935)

0.032

1.233 (0.572–2.660)

0.593

Cardiovascular Mortality

22 (10.4%)

6 (3.0%)

6 (1.7%)

< 0.001

0.298 (0.120–0.737)

0.009

1.782 (0.574–5.533)

0.317

MACE

26 (12.3%)

13 (6.5%)

10 (2.9%)

< 0.001

0.492 (0.245–0.987)

0.046

2.303 (0.991–5.353)

0.053

Hospitalization due to HF

40 (19.0%)

35 (17.4%)

62 (18.1%)

0.92

0.901 (0.546–1.488)

0.685

0.956 (0.605–1.509)

0.845

  1. Abbreviations: HFrEF heart failure with reduced ejection fraction, HFmrEF heart failure with mid-range ejection fraction, HFpEF heart failure with preserved ejection fraction, MACE major adverse cardiac events
  2. Statistically significant variables were highlighted in bold